Relation of Bosentan, Iloprost, and Sildenafil with Growth Factor Levels in Monocrotaline-Induced Pulmonary Hypertension

REFERENCES

• Chin KM, Rubin LJ. Pulmonary arterial hypertension. J Am Coll Cardiol 2008; 51:1527–1538.
   PubMed Web of Science ®Google Scholar
• Said SI. Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2006; 291:L547–L558.
   PubMed Web of Science ®Google Scholar
• Fishman AP. Changing concepts of the pulmonary plexiform lesion. Physiol Res 2000; 49:485–492.
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Gera L, Hirth P, . A bradykinin antagonist and a caspase inhibitor prevent severe pulmonary hypertension in a rat model. Can J Physiol Pharmacol 2002; 80(4):269–274.
   PubMed Web of Science ®Google Scholar
• Jeffery TK, Wanstall JC. Pulmonary vascular remodeling:a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001; 92:1–20.
   PubMed Web of Science ®Google Scholar
• Humbert M, Morrell NW, Archer SL, . Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43:13S–24S.
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995; 8:2129–2138.
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Tuder RM. Cellular and molecular biology of vascular smooth muscle cells in pulmonary hypertension. Pulm Pharmacol Ther 1997; 10:231–241.
   PubMed Web of Science ®Google Scholar
• Chan SY, Loscalzo J. Pathogenic mechanisms of pulmonary arterial hypertension. J Mol Cell Cardiol 2008; 44(1):14–30.
   PubMed Web of Science ®Google Scholar
• Howard LSGE, Morrell NW. New therapeutic agents for pulmonary vascular disease. Paed Resp Rev 2005; 6:285–291.
   Google Scholar
• Lee SH, Rubin LJ. Current treatment strategies for pulmonary arterial hypertension. J Int Med 2005; 258:199–215.
   PubMed Web of Science ®Google Scholar
• Liu C, Liu K, Ji Z, Liu G. Treatments for pulmonary arterial hypertension. Resp Med 2006; 100:765–774.
   PubMed Web of Science ®Google Scholar
• Hoeper M, Galie N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165:1209–1216.
   PubMed Web of Science ®Google Scholar
• Siobal MS. Pulmonary vasodilators. Respir Care 2007; 52(7):885–899.
   PubMed Web of Science ®Google Scholar
• Badesch DB, McLaughlin VV, Delcroix M, . Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43(12):S56–S61.
   PubMed Web of Science ®Google Scholar
• Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension. Eur Respir J 2008; 31:891–901.
   PubMed Web of Science ®Google Scholar
• Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol 2002; 283:L555–L562.
   PubMed Web of Science ®Google Scholar
• Grover TR, Parker TA, Markham NE, Abman SH. rhVEGF treatment preserves pulmonary vascular reactivity and structure in an experimental model of pulmonary hypertension in fetal sheep. Am J Physiol Lung Cell Mol Physiol 2005; 289:L315–L321.
   PubMed Web of Science ®Google Scholar
• Campbell AI, Zhao Y, Sandhu R, Stewart DJ. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001; 104:2242–2248.
   PubMed Web of Science ®Google Scholar
• Gong F, Tang H, Lin Y, . Gene transfer of vascular endothelial growth factor reduces bleomycin-induced pulmonary hypertension in immature rabbits. Pediatr Int 2005; 47:242–247.
   PubMed Web of Science ®Google Scholar
• Roth RA, Reindel JF. Lung vascular injury from monocrotaline pyrrole, a putative hepatic metabolite. Adv Exp Med Biol 1991; 283:477–487.
   PubMedGoogle Scholar
• Wilson D, Segall HJ, Pan LC, . Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit Rev Toxicol 1992; 22(5–6):307–325.
   PubMed Web of Science ®Google Scholar
• Campian ME, Hardziyenka M, Michel MC, Tan HL. How valid are animal models to evaluate treatments for pulmonary hypertension? Naunyn Schmiedebergs Arch Pharmacol 2006; 373(6):391–400.
   PubMed Web of Science ®Google Scholar
• Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008; 155(4):444–454.
   PubMed Web of Science ®Google Scholar
• Arcot SS, Lipke DW, Gillespie MN, Olson JW. Alterations of growth factor transcripts in rat lungs during development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol 1993; 46(6):1086–1091.
   PubMed Web of Science ®Google Scholar
• Partovian C, Adnot S, Eddahibi S, . Heart and lung VEGF mRNA expression in rats with monocrotaline- or hypoxia-induced pulmonary hypertension. Am J Physiol 1998;275(6 Pt 2):H1948–H1956.
   PubMed Web of Science ®Google Scholar
• Boor PJ, Gotlieb AI, Joseph EC, . Chemical-induced vasculature injury. Summary of the symposium presented at the 32nd annual meeting of the Society of Toxicology, New Orleans, Louisiana, March 1993. Toxicol Appl Pharmacol 1995; 132(2):177–195.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995; 95(4):1798–1807.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Voelkel NF, Bates TO, . Prostaglandins induce vascular endothelial growth factor in a human monocytic cell line and rat lungs via cAMP. Am J Respir Cell Mol Biol 1997; 17(6):748–756.
   PubMed Web of Science ®Google Scholar
• Voelkel NF, Vandivier RW, Tuder RM. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006; 290:L209–L221.
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Humbert M, Sediame S, . Imbalance between platelet vascular endothelial growth factor and platelet-derived growth factor in pulmonary hypertension. Effect of prostacyclin therapy. Am J Respir Crit Care Med 2000; 162:1493–1499.
   PubMed Web of Science ®Google Scholar
• Rondelet B, Kerbaul F, Van Beneden R, . Signaling molecules in overcirculation-induced pulmonary hypertension in piglets: effects of sildenafil therapy. Circulation 2004; 110(15):2220–2225.
   PubMed Web of Science ®Google Scholar
• Rondelet B, Kerbaul F, Motte S, . Bosentan for the prevention of overcirculation-induced experimental pulmonary arterial hypertension. Circulation 2003; 107(9):1329–1335.
   PubMed Web of Science ®Google Scholar
• Vidavalur R, Penumathsa SV, Zhan L, Thirunavukkarasu M, Maulik N. Sildenafil induces angiogenic response in human coronary arteriolar endothelial cells through the expression of thioredoxin, hemeoxygenase and vascular endothelial growth factor. Vascul Pharmacol 2006; 45(2):91–95.
   PubMed Web of Science ®Google Scholar
• Iglarz M, Silvestre JS, Duriez M, Henrion D, Lévy BI. Chronic blockade of endothelin receptors improves ischemia-induced angiogenesis in rat hindlimbs through activation of vascular endothelial growth factor-no pathway. Arterioscler Thromb Vasc Biol 2001; 21(10):1598–1603.
   PubMed Web of Science ®Google Scholar
• Tuder RM, Chacon M, Alger L, . Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 2001; 195(3):367–374.
   PubMed Web of Science ®Google Scholar
• Partovian C, Adnot S, Raffestin B, . Adenovirus-mediated lung vascular endothelial growth factor overexpression protects against hypoxic pulmonary hypertension in rats. Am J Respir Cell Mol Biol 2000; 23(6):762–771.
   PubMed Web of Science ®Google Scholar
• Taraseviciene-Stewart L, Kasahara Y, Alger L, . Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001; 15(2):427–438.
   PubMed Web of Science ®Google Scholar
• Grover TR, Parker TA, Zenge JP, . Intrauterine hypertension decreases lung VEGF expression and VEGF inhibition causes pulmonary hypertension in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2003; 284(3):L508–L517.
   PubMed Web of Science ®Google Scholar
• Farkas L, Farkas D, Ask K, . VEGF ameliorates pulmonary hypertension through inhibition of endothelial apoptosis in experimental lung fibrosis in rats. J Clin Invest 2009; 119(5):1298–1311.
   PubMed Web of Science ®Google Scholar
• Fujita M, Mason RJ, Cool C, . Pulmonary hypertension in TNF-alpha-overexpressing mice is associated with decreased VEGF gene expression. J Appl Physiol 2002; 93(6):2162–2170.
   PubMed Web of Science ®Google Scholar
• Botney MD, Bahadori L, Gold LI. Vascular remodeling in primary pulmonary hypertension. Potential role for transforming growth factor-beta. Am J Pathol 1994; 144(2):286–295.
   PubMed Web of Science ®Google Scholar
• Park HK, Park SJ, Kim CS, . Enhanced gene expression of renin-angiotensin system, TGF-beta1, endothelin-1 and nitric oxide synthase in right-ventricular hypertrophy. Pharmacol Res 2001; 43(3):265–273.
   PubMed Web of Science ®Google Scholar
• Morrell NW, Yang X, Upton PD, . Altered growth responses of pulmonary artery smooth muscle cells from patients with primary pulmonary hypertension to transforming growth factor-beta(1) and bone morphogenetic proteins. Circulation 2001; 104(7):790–795.
   PubMed Web of Science ®Google Scholar
• El-Haroun H, Clarke DL, Deacon K, . IL-1beta, BK, and TGF-beta1 attenuate PGI2-mediated cAMP formation in human pulmonary artery smooth muscle cells by multiple mechanisms involving p38 MAP kinase and PKA. Am J Physiol Lung Cell Mol Physiol 2008; 294(3):L553–L562.
   PubMed Web of Science ®Google Scholar
• Markewitz BA, Farrukh IS, Chen Y, Li Y, Michael JR. Regulation of endothelin-1 synthesis in human pulmonary arterial smooth muscle cells. Effects of transforming growth factor-beta and hypoxia. Cardiovasc Res 2001; 49(1):200–206.
   PubMed Web of Science ®Google Scholar
• Pertovaara L, Kaipainen A, Mustonen T, . Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. J Biol Chem 1994; 269(9):6271–6274.
   PubMed Web of Science ®Google Scholar
• Tzanidis A, Lim S, Hannan RD, . Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). J Mol Cell Cardiol 2001; 33(5):969–981.
   PubMed Web of Science ®Google Scholar